This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →
Consolidated Q2 FY27 revenue falls 29.8% and profit after tax falls 56.8% versus Q2 FY26
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Consolidated Q2 FY27 revenue from operations fell 29.8% to Rs 4,247 crore from Rs 6,047 crore a year earlier; profit after tax fell 56.8% to Rs 264 crore from Rs 610 crore. A Rs 284 crore exceptional charge, including a US$15 million settlement, cut pre-tax profit to Rs 338 crore. Operating margin before interest, depreciation and tax narrowed to 20.3% from 39.0%. For the consolidated half year, operating cash flow was negative Rs 203 crore.
Revenue, profit and margins fell, while half-year operating cash flow was negative. Legal costs and weak sales add pressure despite quarterly profit.
| Q2 FY27 | Q2 FY26 | Change | |
|---|---|---|---|
| Revenue | ₹4,157 Cr | ₹6,047 Cr | −31.3% |
| Operating profit | ₹529.4 Cr | ₹2,152 Cr | −75.4% |
| Profit after tax | ₹263.8 Cr | ₹610.4 Cr | −56.8% |
| EBITDA margin | 11.8% | 16.1% | −4.3 pp |
From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.